---
document_datetime: 2023-09-21 17:31:22
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-teva-generics-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-teva-generics-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2053252
conversion_datetime: 2025-12-28 00:13:01.300089
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Zoledronic acid Teva Generics

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on product no   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------------------------|-----------|
| IAIN/0002            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                            | 03/10/2014                                                                               | SmPC, Labelling and PL           |           |
| IB/0001              | Update of SmPC section 4.2 to place the information on hydration and calcium intake to the beginning of the section instead of under the subheading Paget`s disease. And update of sections 4.4 and 4.8 of the SmPC to clarify that reporting of osteonecrosis of the | 06/08/2014                                                                               | SmPC                             |           |

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| jaw is not limited to cancer patients, and to add 'anti-angiogenic medicinal products\" to the concomitant risk factors for ONJ, according to the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Medicinal product no longer authorised